JP2016501538A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016501538A5 JP2016501538A5 JP2015548131A JP2015548131A JP2016501538A5 JP 2016501538 A5 JP2016501538 A5 JP 2016501538A5 JP 2015548131 A JP2015548131 A JP 2015548131A JP 2015548131 A JP2015548131 A JP 2015548131A JP 2016501538 A5 JP2016501538 A5 JP 2016501538A5
- Authority
- JP
- Japan
- Prior art keywords
- rna
- therapeutic composition
- rhabdovirus
- cross
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261740856P | 2012-12-21 | 2012-12-21 | |
| US61/740,856 | 2012-12-21 | ||
| US201361835310P | 2013-06-14 | 2013-06-14 | |
| US61/835,310 | 2013-06-14 | ||
| PCT/CA2013/051009 WO2014094182A1 (en) | 2012-12-21 | 2013-12-20 | Non-replicating virus-derived particles and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019165067A Division JP2020014467A (ja) | 2012-12-21 | 2019-09-11 | 非複製型ウイルス由来粒子及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016501538A JP2016501538A (ja) | 2016-01-21 |
| JP2016501538A5 true JP2016501538A5 (enExample) | 2017-02-02 |
| JP6612619B2 JP6612619B2 (ja) | 2019-11-27 |
Family
ID=50977496
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015548131A Expired - Fee Related JP6612619B2 (ja) | 2012-12-21 | 2013-12-20 | 非複製型ウイルス由来粒子及びその使用 |
| JP2019165067A Pending JP2020014467A (ja) | 2012-12-21 | 2019-09-11 | 非複製型ウイルス由来粒子及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019165067A Pending JP2020014467A (ja) | 2012-12-21 | 2019-09-11 | 非複製型ウイルス由来粒子及びその使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11110138B2 (enExample) |
| EP (1) | EP2935569B1 (enExample) |
| JP (2) | JP6612619B2 (enExample) |
| KR (1) | KR102167497B1 (enExample) |
| CN (1) | CN105121636A (enExample) |
| AU (1) | AU2013362761B2 (enExample) |
| BR (1) | BR112015015045A8 (enExample) |
| CA (1) | CA2896162C (enExample) |
| CL (1) | CL2015001738A1 (enExample) |
| ES (1) | ES2745599T3 (enExample) |
| IL (1) | IL239486B (enExample) |
| MX (1) | MX376266B (enExample) |
| MY (1) | MY174912A (enExample) |
| PH (1) | PH12015501442A1 (enExample) |
| RU (1) | RU2705556C2 (enExample) |
| SG (2) | SG10201704903YA (enExample) |
| WO (1) | WO2014094182A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2896162C (en) * | 2012-12-21 | 2021-10-12 | Ottawa Hospital Research Institute | Non-replicating virus-derived particles and uses thereof |
| US11040027B2 (en) | 2017-01-17 | 2021-06-22 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| CN109985244A (zh) * | 2017-12-29 | 2019-07-09 | 广州威溶特医药科技有限公司 | E3连接酶抑制剂和溶瘤病毒在制备抗肿瘤药物的应用 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| CN109432098B (zh) * | 2018-11-20 | 2021-04-13 | 天津大学 | 化合物ps-341在制备小rna病毒科肠道病毒属病毒抑制剂的应用 |
| EP3708176A1 (en) * | 2019-03-15 | 2020-09-16 | Centre National De La Recherche Scientifique -Cnrs- | Mutant vsv ectodomain polypeptide and uses thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5106619A (en) | 1983-12-20 | 1992-04-21 | Diamond Scientific Co. | Preparation of inactivated viral vaccines |
| IL153570A0 (en) | 2000-06-26 | 2003-07-06 | Wellstat Biologics Corp | Purging of cells using viruses |
| AU2003268505A1 (en) * | 2002-09-09 | 2004-03-29 | University Of Tennessee Research Foundation | Recombinatant mutants of rhabdovirus and methods of use thereof |
| JP4708027B2 (ja) | 2002-10-01 | 2011-06-22 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | 抗癌組成物および抗感染疾患組成物ならびにこれらを使用する方法 |
| CN100579579C (zh) * | 2002-10-01 | 2010-01-13 | 诺华疫苗和诊断公司 | 抗癌及抗感染性疾病组合物及其使用方法 |
| EP2301573A1 (en) | 2002-10-01 | 2011-03-30 | Novartis Vaccines and Diagnostics, Inc. | Anti-cancer and anti-infectious disease compositions and methods for using same |
| ES2319424T3 (es) | 2003-03-27 | 2009-05-07 | Ottawa Health Research Institute | Virus mutantes de la estomatitis vesivular y sus usos. |
| EP1726647B1 (en) * | 2004-03-19 | 2015-01-07 | GenomIdea, Inc. | Gene promoting vascular endothelial cell growth |
| US8703467B2 (en) * | 2004-05-27 | 2014-04-22 | Baxter International Inc. | Inactivation of a pathogen in a sample by a treatment with formalin and UV light |
| CA2921063C (en) | 2006-09-15 | 2020-01-28 | Ottawa Hospital Research Institute | Oncolytic rhabdovirus |
| ES2532808T3 (es) | 2008-09-16 | 2015-03-31 | Genomidea Inc. | Agente terapéutico/profiláctico para cáncer de próstata |
| CN102858959B (zh) | 2009-12-10 | 2016-02-24 | 渥太华医院研究院 | 溶瘤弹状病毒 |
| RU2013139565A (ru) | 2011-01-27 | 2015-03-10 | Лентиджен Корпорейшн | Усовершенствованная праймерная и бустерная вакцина |
| CN103415797B (zh) * | 2011-02-02 | 2016-01-27 | 康宁光缆系统有限责任公司 | 适用于为设备机架中的光学底板建立光学连接的稠密光纤连接器总成及相关的连接器与缆线 |
| WO2012122649A1 (en) | 2011-03-15 | 2012-09-20 | Ottawa Hospital Research Institute | Recombinant orf virus |
| US9623096B2 (en) * | 2011-11-09 | 2017-04-18 | Celverum Inc. | Virally infected hematopoietic cells and uses thereof |
| CA2896162C (en) * | 2012-12-21 | 2021-10-12 | Ottawa Hospital Research Institute | Non-replicating virus-derived particles and uses thereof |
-
2013
- 2013-12-20 CA CA2896162A patent/CA2896162C/en not_active Expired - Fee Related
- 2013-12-20 KR KR1020157019923A patent/KR102167497B1/ko not_active Expired - Fee Related
- 2013-12-20 JP JP2015548131A patent/JP6612619B2/ja not_active Expired - Fee Related
- 2013-12-20 AU AU2013362761A patent/AU2013362761B2/en not_active Ceased
- 2013-12-20 CN CN201380071341.1A patent/CN105121636A/zh active Pending
- 2013-12-20 SG SG10201704903YA patent/SG10201704903YA/en unknown
- 2013-12-20 ES ES13865170T patent/ES2745599T3/es active Active
- 2013-12-20 SG SG11201504843UA patent/SG11201504843UA/en unknown
- 2013-12-20 MY MYPI2015702052A patent/MY174912A/en unknown
- 2013-12-20 RU RU2015128766A patent/RU2705556C2/ru active
- 2013-12-20 BR BR112015015045A patent/BR112015015045A8/pt not_active Application Discontinuation
- 2013-12-20 EP EP13865170.8A patent/EP2935569B1/en active Active
- 2013-12-20 WO PCT/CA2013/051009 patent/WO2014094182A1/en not_active Ceased
- 2013-12-20 US US14/654,259 patent/US11110138B2/en not_active Expired - Fee Related
- 2013-12-20 MX MX2015008155A patent/MX376266B/es active IP Right Grant
-
2015
- 2015-06-17 IL IL239486A patent/IL239486B/en active IP Right Grant
- 2015-06-18 CL CL2015001738A patent/CL2015001738A1/es unknown
- 2015-06-19 PH PH12015501442A patent/PH12015501442A1/en unknown
-
2019
- 2019-09-11 JP JP2019165067A patent/JP2020014467A/ja active Pending
-
2021
- 2021-07-21 US US17/382,146 patent/US20210346441A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016501538A5 (enExample) | ||
| Choi et al. | Polymeric oncolytic adenovirus for cancer gene therapy | |
| Naik et al. | Curative one-shot systemic virotherapy in murine myeloma | |
| Di Gioia et al. | Nanocomplexes for gene therapy of respiratory diseases: Targeting and overcoming the mucus barrier | |
| JP2019507761A5 (enExample) | ||
| Alemany | Viruses in cancer treatment | |
| Liu et al. | Subunit nanovaccine with potent cellular and mucosal immunity for COVID-19 | |
| Zhu et al. | Development and application of oncolytic viruses as the nemesis of tumor cells | |
| JP2018502120A5 (enExample) | ||
| JP2018530624A5 (enExample) | ||
| EP3492597A3 (en) | Capsid-modified, raav3 vector compositions and methods of use in gene therapy of human liver cancer | |
| JP2011519869A5 (enExample) | ||
| JP2020533411A5 (enExample) | ||
| JP2017538680A5 (enExample) | ||
| JP2019523648A5 (enExample) | ||
| JP2016501013A5 (enExample) | ||
| JP2019508045A5 (enExample) | ||
| RU2015128766A (ru) | Нереплицируемые происходящие от вирусов частицы и их применение | |
| JP2018023397A5 (enExample) | ||
| WO2011150127A3 (en) | Novel systems, vectors, and methods for delivery of biomolecules to eukaryotic cells | |
| JP2013537426A5 (enExample) | ||
| BRPI0816134A2 (pt) | Herpesvírus, sequência de dna, vetor, célula, vírus, método para produção de partículas infecciosas, partículas infecciosas, vacina, uso de herpesvírus ou da sequência de dna ou do vetor ou das partículas infecciosas, e, método para o tratamento preventivo e/ou terapêutico de uma doença. | |
| JP2019531293A5 (enExample) | ||
| JP2018536002A5 (enExample) | ||
| Koellhoffer et al. | Inactivated cowpea mosaic virus in combination with OX40 agonist primes potent antitumor immunity in a bilateral melanoma mouse model |